Evidence map›Paper›PMID 11960337›Full record

ArticleLeukemia2002

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

F Lefrère, A Delmer, F Suzan, V Levy, C Belanger, M Djabarri, B Arnulf, G Damaj, N Maillard, V Ribrag and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Non-Hodgkin's lymphomas, version 4.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014
    Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Proteasome inhibitors in mantle cell lymphoma.Best practice & research. Clinical haematology · 2012
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 1 country.

F LefrèreService d'Hématologie Adultes, Hôpital Necker, Paris, France.
A Delmer
F Suzan
V Levy
C Belanger
M Djabarri
B Arnulf
G Damaj
N Maillard
V Ribrag
M Janvier
C Sebban
R-O Casasnovas
R Bouabdallah
F Dreyfus
V Verkarre
E Delabesse
F Valensi
E McIntyre
N Brousse
B Varet
O Hermine
Hôpital Necker-Enfants Malades · FRHôpital Cochin · FRCentre Hospitalier Universitaire Dijon Bourgogne · FRHôpital André Mignot · FRHôpital Edouard Herriot · FRHôpital René Huguenin · FRHôpital Saint-Louis · FRHôtel-Dieu de Paris · FRInstitut Gustave Roussy · FRInstitut Paoli-Calmettes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a distinct clinico-pathological entity with a poor prognosis. We have conducted a prospective study in patients with MCL to evaluate a therapeutic strategy in which CHOP polychemotherapy was followed by DHAP if CHOP failed to induce complete remission. Responding patients then proceeded to an intensification therapy with autologous peripheral blood stem cell transplantation (APBSCT). Twenty-eight consecutive patients with newly diagnosed aggressive MCL were included. After four cycles of CHOP regimen, two complete responses (CR) were obtained (7%) and 14 (50%), five (18%) and seven (25%) patients achieved partial (PR), minor (MR) and no response, respectively (one patient died from septic complications during CHOP induction). The two patients in CR after CHOP underwent intensification with TBI, high-dose cyclophosphamide-etoposide and APBSCT. The other twenty-five patients received DHAP and in this group a response rate of 92% (21 CR (84%), two PR (8%)) was observed. Two patients had progressive disease. The twenty-three responding patients received high-dose therapy (TAM8 regimen: TBI-cytarabine-melphalan) followed by APBSCT. One of the two partial responding patients achieved CR after TAM8. After a median follow-up of 47.6 months (range, 14-70), seven patients have relapsed. Our data confirm that: (1) CHOP regimen induces a low CR rate in MCL; (2) CHOP plus DHAP appears to be much more efficient and allows a large proportion of patients to proceed to high-dose therapy in CR; (3) consolidation therapy including TBI and high-dose Arac-C followed by APBSCT may improve event-free survival.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsCisplatinCyclophosphamideCytarabineDexamethasoneDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansImmunophenotypingLymphoma, Mantle-CellMaleMiddle AgedCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinPrednisoneVincristine

Identifiers

PMID11960337
OpenAlexW2041423582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.